Neoadjuvant chemotherapy for primary adenocarcinomas of the urinary bladder: a single-site experience

详细信息    查看全文

• 作者：Bin Yu (1) (2)
  Jin Zhou (3)
  Hongzhou Cai (1)
  Ting Xu (1)
  Zicheng Xu (1) (2)
  Qing Zou (1)
  Min Gu (2)
  
  1. Department of Urologic Surgery ; Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University ; Nanjing ; China
  2. Department of Urology ; First Affiliated Hospital of Nanjing Medical University ; Nanjing ; China
  3. Department of Hospital Infection Control ; Affiliated Cancer Hospital of Jiangsu Province of Nanjing Medical University ; Nanjing ; China
  
• 关键词：Neoadjuvant chemotherapy ; Primary adenocarcinomas of bladder ; Survival
• 刊名：BMC Urology
• 出版年：2015
• 出版时间：December 2015
• 年：2015
• 卷：15
• 期：1
• 全文大小：53 KB
• 参考文献：1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. / CA Cancer J Clin 2011,61(2):69-0. 10.3322/caac.20107 CrossRef
  2. Abol-Enein H, Kava BR, Carmack AJ: Nonurothelial cancer of the bladder. / Urology 2007,69(1 Suppl):93-04. CrossRef
  3. Dahm P, Gschwend JE: Malignant non-urothelial neoplasms of the urinary bladder: a review. / Eur Urol 2003,44(6):672-1. 10.1016/S0302-2838(03)00416-0 CrossRef
  4. Calabro F, Sternberg CN: Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer. / Eur Urol 2009,55(2):348-8. 10.1016/j.eururo.2008.10.016 CrossRef
  5. Clark PE: Neoadjuvant versus adjuvant chemotherapy for muscle-invasive bladder cancer. / Expert Rev Anticancer Ther 2009,9(6):821-0. 10.1586/era.09.36 CrossRef
  6. Logothetis CJ, Samuels ML, Ogden S: Chemotherapy for adenocarcinomas of bladder and urachal origin: 5-fluorouracil, doxorubicin, and mitomycin-C. / Urology 1985,26(3):252-. 10.1016/0090-4295(85)90121-9 CrossRef
  7. Siefker-Radtke AO, Gee J, Shen Y, Wen S, Daliani D, Millikan RE, / et al.: Multimodality management of urachal carcinoma: the M. D. Anderson Cancer Center experience. / J Urol 2003,169(4):1295-. 10.1097/01.ju.0000054646.49381.01 CrossRef
  8. von der Maase H, Hansen SW, Roberts JT, Dogliotti L, Oliver T, Moore MJ, / et al.: Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. / J Clin Oncol 2000,18(17):3068-7.
  9. Sohaib A: RECIST rules. / Cancer Imaging 2012, 12:345-. 10.1102/1470-7330.2012.9011 CrossRef
  10. Ploeg M, Aben KK, de Hulsbergen-van Kaa CA, Schoenberg MP, Witjes JA, Kiemeney LA: Clinical epidemiology of nonurothelial bladder cancer: analysis of the Netherlands Cancer Registry. / J Urol 2010,183(3):915-0. 10.1016/j.juro.2009.11.018 CrossRef
  11. Johnson DE, Hogan JM, Ayala AG: Primary adenocarcinoma of the urinary bladder. / South Med J 1972,65(5):527-0. 10.1097/00007611-197205000-00004 CrossRef
  12. Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, / et al.: Capecitabine and oxaliplatin for advanced esophagogastric cancer. / N Engl J Med 2008,358(1):36-6. 10.1056/NEJMoa073149 CrossRef
  13. Kang YK, Kang WK, Shin
• 刊物主题：Urology/Andrology; Internal Medicine;
• 出版者：BioMed Central
• ISSN：1471-2490

文摘

Background Adenocarcinoma of the urinary bladder is a rare malignancy. Radical surgery is suggested as the best available treatment for early-stage disease, but there is currently no consensus on standard chemotherapy regimen for advanced stage. We assessed the feasibility and effect of neoadjuvant chemotherapy with gemcitabine and cisplatin (GC) plus S-1 for patients with locally advanced primary adenocarcinomas of the urinary bladder. Methods Six patients with locally advanced urachal or non-urachal (n--, each) primary adenocarcinoma of the bladder were treated from October 2010 to October 2013 at a single center. All the patients were treated with 3?cycles (21d, each) of GC plus S-1 (gemcitabine, 1000?mg/m2, days 1 and 8; cisplatin, 70?mg/m2, day 2; and S-1, 50?mg bid, day 1-14). After neoadjuvant chemotherapy, patients with urachal cancer were treated with en bloc radical cystectomy and umbilectomy; the remaining 3 patients were treated with cystectomy. Results All patients successfully completed the neoadjuvant chemotherapy without serious side effects. Two patients were assessed as complete response, 2 as partial response, 1 as stable disease and 1 as progressive disease. Conclusions Despite the limitations of a small study population, the GC plus S-1 regimen for locally advanced primary adenocarcinoma of the urinary bladder was effective, and facilitated the success of surgery to a certain extent. Short follow-up time was also a limitation of our study. More studies are needed to evaluate the results.